Skip to content

Gastrostomy-Biliary Diversion: Innovative Management for Bile Canalicular Transport Disorders

Gastrostomy-Biliary Diversion: Innovative Management for Children With Bile Canalicular Transport Disorders

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04071197
Enrollment
20
Registered
2019-08-28
Start date
2020-03-10
Completion date
2021-04-01
Last updated
2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive Familial Intrahepatic Cholestasis

Keywords

bile canalicular transport disorders

Brief summary

Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders that can present early in life with cholestasis and intractable pruritus. Their treatment poses a great challenge, with medical treatment is not successful in many cases. Moreover, the available non-transplant surgeries carry many side effects and different degrees of efficacy. Partial external biliary diversion, internal biliary diversion, and ileal exclusion still lack widespread experience with many side effects. Nasobiliary stent placement has little tolerability, especially in younger age. Gastrobiliary tube is a novel modality for external biliary diversion in such patients.

Detailed description

Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders that can present early in life with cholestasis and intractable pruritus. They result primarily from defective transporters of different bile constituents on the canalicular membrane. The mildest form of these defective transporters can present by what is called benign recurrent intrahepatic cholestasis (BRIC). More recently both disease categories that represent the severest (PFIC) and mildest (BRIC) forms of these transporters are better nomenclated as bile canalicular transport disorders, as some cases can start early as BRIC and later in life progress the PFIC phenotype. Moreover, a continuous spectrum of severity is present between what were previously known as PFIC and BRIC. If the severest forms are not treated effectively they can have devastating outcomes reaching death. On the other hand, those known as BRIC can have severe attacks with unremitting pruritus that could be prolonged and sometimes persistent. Their treatment poses a great challenge, with medical treatment is not successful in many cases. Moreover, the available non-transplant surgeries carry many side effects and different degrees of efficacy. Partial external biliary diversion is not always successful and has disfiguring effects and the stoma can have many side effects. Internal biliary diversion and ileal exclusion still lack widespread experience and encouraging results due to sometimes lack of efficacy and others due to side effects. Nasobiliary stent placement was tried in previous cases with a promising outcome, but with little tolerability, especially in younger age. In spite liver transplant is the last resort for failing cases, the availability of successful non transplant therapy would be the preferable one if it is with adequate efficacy and little side effects. The innovative intervention proposed in this study is expected to have a good efficacy due to total biliary diversion rather than the partial ones obtained by other surgeries. Moreover, it avoids the disfiguring impact of the jeujenal stoma. More importantly, it can be removed at any time and be used at the times of severe flare of the disease.

Interventions

DEVICEGastostomy-biliary tube

gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril

DEVICEExternal biliary diversion, internal biliary diversion and nasobiliary tube

All biliary diversion modalities other than gastrobiliary tube

Sponsors

National Liver Institute, Egypt
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The study group will be subjected to gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril

Eligibility

Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* PFIC cases that are previously responding to medical treatment with recent flare of the disease that doesn't respond to medical therapy * PFIC cases that are not responding to medical treatment and refusing non-transplant surgery and not indicated for liver transplant * BRIC cases with frequent attacks not responding to medical therapy and refusing or unable to tolerate nasobiliary stent

Exclusion criteria

* Severe portal hypertensive gastropathy * Decompensated cirrhosis

Design outcomes

Primary

MeasureTime frameDescription
Occurrence of bleeding6 monthsnumber of patients with bleeding
Occurrence of infection6 monthsnumber of patients with infection

Secondary

MeasureTime frameDescription
Serum bilirubin level12 monthsnumber of patients with normal bilirubin
Improvement of pruritus12 monthsnumber of patients with no pruritus

Countries

Egypt

Contacts

Primary ContactAhmad M Sira, M.D.
asira@liver.menofia.edu.eg; ahmadsira@hotmail.com+2-048-222-2740

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026